RecruitingPhase 3NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Sponsor
Clarity Pharmaceuticals Ltd
Enrollment
220 participants
Start Date
May 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Eligibility
Sex: MALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is a Phase 3 trial testing a specialized PET scan using a radioactive tracer called 64Cu-SAR-bisPSMA to detect where prostate cancer has returned after initial treatment (called biochemical recurrence, when PSA levels rise again after surgery or radiation).
**You may be eligible if...**
- You are 18 or older with a confirmed history of prostate cancer (adenocarcinoma)
- You have had definitive treatment (surgery or radiation) and now have rising PSA levels suggesting the cancer is returning
- You are potentially eligible for additional local or regional treatments aimed at cure
- Your life expectancy is at least 6 months
**You may NOT be eligible if...**
- You have already confirmed spread of cancer to distant organs beyond the local/regional area
- You have a condition preventing you from receiving the radioactive tracer or undergoing a PET scan
- You are pregnant or breastfeeding
- You have had prior treatments that would affect PSA interpretation in ways that interfere with study goals
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG64Cu-SAR-bisPSMA
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA
Locations(28)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06970847
Related Trials
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT046926751 location
DESTINY-PANTUMOUR04
NCT0712400017 locations
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT0700515433 locations
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
NCT068073593 locations
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT0733644618 locations